U.S. Markets open in 8 hrs 33 mins

These New Products Are Driving AstraZeneca’s Growth in Fiscal 2018

Margaret Patrick
These New Products Are Driving AstraZeneca’s Growth in Fiscal 2018

How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca reported oncology revenues of $4.26 billion, which is a YoY increase of 47% on an actual basis and 44% on a constant exchange rate (or CER) basis. In the first nine months of 2018, AstraZeneca reported new cardiovascular, renal, and metabolism (or CVRM) product sales worth $2.90 billion, which is a YoY rise of 14% on an actual basis and 12% on a CER basis.